Redeye’s first comments on CellaVision’s report for the Q3 report showed sales considerably lower than expected at SEK 88m vs. our SEK 117m. The gross margin was also lower at 65% compared with the 68% expected. Even though the deviation was a bit larger than we had hoped for, we still have a positive long-term view, and the clearance of DC-1 in the US is good news for the long term prospects. Any significant dips can provide good opportunities to buy the share.